Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1).

Poeppel, T D; Boy, Christian; Bockisch, A; Kotzerke, J; Buchmann, I; Ezziddin, S; Scheidhauer, K; Krause, B J; Schmidt, D; Amthauer, H; Rösch, F; Nagarajah, J; Führer, D; Lahner, H; Pöpperl, G; Hörsch, D; Walter, Martin Alexander; Baum, R P (2015). Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1). Nuklearmedizin / Nuclear medicine, 54(1), pp. 1-11. Schattauer

[img] Text
Peptid-Rezeptor-Radionuklid-Therapie (PRRT) Somatostatin Rezeptor exprimierender Tumore_WAL.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (206kB) | Request a copy

This document describes the guideline for peptide receptor radionuclide therapy (PRRT) published by the German Society of Nuclear Medicine (DGN) and accepted by the Association of the Scientific Medical Societies in Germany (AWMF) to be included in the official AWMF Guideline Registry. These recommendations are a prerequisite for the quality management in the treatment of patients with somatostatin receptor expressing tumours using PRRT. They are aimed at guiding nuclear medicine specialists in selecting likely candidates to receive PRRT and to deliver the treatment in a safe and effective manner. The recommendations are based on an interdisciplinary consensus. The document contains background information and definitions and covers the rationale, indications and contraindications for PRRT. Essential topics are the requirements for institutions performing the therapy, e. g. presence of an expert for medical physics, intense cooperation with all colleagues involved in the treatment of a patient, and a certificate of instruction in radiochemical labelling and quality control are required. Furthermore, it is specified which patient data have to be available prior to performance of therapy and how treatment has to be carried out technically. Here, quality control and documentation of labelling are of great importance. After treatment, clinical quality control is mandatory (work-up of therapy data and follow-up of patients). Essential elements of follow-up are specified in detail. The complete treatment inclusive after-care has to be realised in close cooperation with the involved medical disciplines. Generally, the decision for PRRT should be undertaken within the framework of a multi-disciplinary tumour board.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Pavillon 52 > Forschungsgruppe Klinische Radiopharmazie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Pavillon 52 > Forschungsgruppe Klinische Radiopharmazie

UniBE Contributor:

Boy, Christian and Walter, Martin Alexander

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0029-5566

Publisher:

Schattauer

Language:

German

Submitter:

Franziska Nicoletti

Date Deposited:

31 Mar 2015 09:43

Last Modified:

30 Oct 2019 20:26

PubMed ID:

25683107

Uncontrolled Keywords:

DOTATATE, DOTATOC, NEN, NET, Neuroendocrine tumour, PRRT, guideline, peptide receptor radionuclide therapy

BORIS DOI:

10.7892/boris.67180

URI:

https://boris.unibe.ch/id/eprint/67180

Actions (login required)

Edit item Edit item
Provide Feedback